Rova-T (Rovalpituzumab tesirine) is part of a biomarker-specific antibody drug conjugate that specifically targets the protein DLL3 in cancer stem cells. There has been recent data about Rova-T from the European Society of Medical Oncology, showing an overall response rate amounting to 44 percent for DLL-expressing small cell lung cancer (SCLC) patients.

AbbVie estimates that it will commercialize Rova-T in 2018, gaining a multibillion-dollar surge in its revenue.

This acquisition improves and expands the company’s current oncology pipeline, adding four new early-stage clinical compounds. These have solid tumor indications. The company has also gained a notable portfolio of preclinical information.

"AbbVie is committed to continued innovation in oncology, a critical component of our long-term growth and an area of significant need to millions of patients worldwide," Richard Gonzalez, chairman and CEO of AbbVie, said. "The addition of Stemcentrx and its late-stage compound Rova-T provide AbbVie with a unique platform in solid tumor therapeutics and complement our leadership position in hematologic oncology. We believe the acquisition of Stemcentrx will strengthen and accelerate our ability to deliver innovative therapies that will have a remarkable impact on patients' lives."